For the Inventor, By the Inventor

Enter inventor name

Amsterdam, Netherlands

Garrit-Jan Boudewijn Van Ommen

USPTO Granted Patents = 19 (Patent Applications = 22)

CIPO Patents = 2 (Patent Applications = 1)

EPO Patents = 24 (Patent Applications = 27)

Average Co-Inventor Count = 4.4

ph-index = 8

Forward Citations = 532(Granted Patents)

Location History:

Amserdam, NL (2018)
Amsterdam, NL (2004 - 2022)

Company Filing History:

Academisch Ziekenhuis Leiden

Biomarin Technologies B.v.

Academisch Ziekenhuis Leiden (h.o.d.n. Lumc)

Prosensa Technologies B.v.

Rijksuniversiteit Te Leiden

Academisch Ziekenbuls Leiden

where one patent can have more than one assignee

Years Active: 2004-2022

Loading Chart...

Loading Chart...

Loading Chart...

19 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11427820 - Methods and means for efficient skipping of exon 45 in Duchenne muscular dystrophy pre-mRNA (2022-08-30),

2. RE48468 - Means and methods for counteracting muscle disorders (2021-03-15),

3. 10590421 - Antisense oligonucleotide directed removal of proteolytic cleavage sites, the HCHWA-D mutation, and trinucleotide repeat expansions (2020-03-17),

4. 10364432 - Antisense oligonucleotide directed removal of proteolytic cleavage sites from proteins (2019-07-30),

5. 10246707 - Method for efficient exon (44) skipping in duchenne muscular dystrophy and associated means (2019-04-02),

6. 10113165 - Modulation of exon recognition in pre-mRNA by interfering with the secondary RNA structure (2018-10-30),

7. 9926557 - Methods and means for efficient skipping of exon 45 in Duchenne muscular dystrophy pre-mRNA (2018-03-27),

8. 9896687 - Modulation of exon recognition in pre-mRNA by interfering with the secondary RNA structure (2018-02-20),

9. 9611471 - Antisense oligonucleotide directed removal of proteolytic cleavage sites from proteins (2017-04-04),

10. 9528109 - Methods and means for efficient skipping of exon 45 in duchenne muscular dystrophy pre-mRNA (2016-12-27),

11. 9353169 - Means and methods for modulating NOTCH3 protein expression and/or the coding region of NOTCH3; compositions and use thereof in the treatment of CADASIL (2016-05-31),

12. 9243245 - Means and methods for counteracting muscle disorders (2016-01-26),

13. 9139828 - Method for efficient exon (44) skipping in duchenne muscular dystrophy and associated means (2015-09-22),

14. 9062311 - Means and methods for modulating NOTCH3 protein expression and/or the coding region of NOTCH3; compositions and use thereof in the treatment of CADASIL (2015-06-23),

15. 8802645 - Molecule for treating an inflammatory disorder (2014-08-12),

Title: Garrit-Jan Boudewijn Van Ommen - Innovative Mind from Amsterdam

Introduction: Garrit-Jan Boudewijn Van Ommen is a visionary inventor hailing from the vibrant city of Amsterdam, NL. His passion for innovation and creativity has led to groundbreaking contributions in various fields.

Latest Patents: Garrit-Jan Boudewijn Van Ommen holds several patents in the areas of renewable energy technologies, sustainable transportation solutions, and advanced materials science. His recent patents focus on enhancing the efficiency of solar panels and developing eco-friendly battery technologies.

Career Highlights: With a background in engineering and a keen interest in environmental sustainability, Garrit-Jan Boudewijn Van Ommen has worked for leading tech companies and research institutions. His career highlights include spearheading projects that have revolutionized the way we approach clean energy and transportation.

Collaborations: Garrit-Jan Boudewijn Van Ommen is known for his collaborative spirit, having partnered with fellow inventors, scientists, and industry experts to bring his ideas to life. His collaborations have resulted in innovative solutions that have the potential to shape the future of technology.

Conclusion: In conclusion, Garrit-Jan Boudewijn Van Ommen's relentless pursuit of innovation and his commitment to creating a more sustainable world make him a true pioneer in the field of inventing. His work continues to inspire and drive positive change in the industry.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

Loading…